Opinion|Videos|February 17, 2025
Sequencing Sections for Patients With Both BRCA Mutations and Early-Stage TNBC
Author(s)Rebecca A. Shatsky, MD, Casey Degen, MD
Panelists discuss factors influencing the decision to continue adjuvant immunotherapy for patients achieving pathologic complete response (pCR) with pembrolizumab-containing therapy, weighing the benefits against risks and considering the role of biomarkers. They also explore sequencing decisions for patients with both BRCA mutations and early-stage triple-negative breast cancer (TNBC), focusing on the prioritization of PARP inhibition versus immunotherapy and situations where both may be recommended. Additionally, they discuss approaches to monitoring and managing immune-related adverse events, including baseline screening and ongoing management protocols.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr. Shatsky asks Dr. Degen: For patients achieving pCR with pembrolizumab-containing therapy, what factors influence your decision about adjuvant immunotherapy continuation? (31: 28 -
- How do you weigh the potential benefits against risks?
- What role do biomarkers play in this decision?
- Dr. Degen asks Dr. Shatsky: How do you approach sequencing decisions for patients with both BRCA mutations and early-stage TNBC? (33:51
- What factors guide your prioritization of PARP inhibition versus immunotherapy?
- Are there specific scenarios where you recommend both approaches?
- Dr. Shatsky asks Dr. Degen: Could you discuss your approach to immune-related adverse event monitoring and management?
- What is your protocol for baseline screening and ongoing monitoring?
Advertisement
Related to this article
Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.
A study found that the vast majority of veterans with early prostate cancer pursued surveillance instead of treatment.
The oral OMNI-EGFR inhibitor earned fast track status for advanced EGFR C797S–positive non–small cell lung cancer that progressed on a third-generation EGFR TKI.
The oral PARG inhibitor ETX-19477 earned fast track status for BRCA-mutated, HR-positive, HER2-negative unresectable or metastatic breast cancer.
Weekly oral dordaviprone maintenance after allogeneic transplant produced no DLTs and low rates of grade 3/4 cytopenias in high-risk AML and MDS.
An analysis of 12 randomized trials validated MRD-negative CR as a surrogate for PFS in earlier-line relapsed/refractory multiple myeloma.
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
Lisa Niswander, MD, PhD, of Roswell Park, is investigating ways to combine CAR T cells and a new class of targeted cancer drugs for younger leukemia.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC
2
FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer
3
Dr Leary on a Neo-Epitope-Based Vaccine With or Without Pembrolizumab in Platinum-Sensitive Recurrent Ovarian Cancer
4
NMA Associates MRD-Negative CR With PFS in Earlier-Line R/R Myeloma
5